AbbVie scientists discovered and developed Rinvoq. Credit: © AbbVie Inc. All rights reserved. AbbVie has reported encouraging topline outcomes from the first of two ...

Eli Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after over three years of treatment.

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.